Photocure ASA. The world leader in photodynamic technology. Sept Ketil F. Widerberg, Director Business Development
|
|
- Domenic Briggs
- 7 years ago
- Views:
Transcription
1 Brilliance in photodynamic technology Photocure ASA The world leader in photodynamic technology Sept 2011 Ketil F. Widerberg, Director Business Development
2 Photocure Mission Mission To bring innovative solutions to patients and consumers worldwide, through efficient development and commercialisation of photodynamic technology 2
3 Photocure - The World Leader in Photodynamic Technology (PDT) PDT is a unique technology where drugs combined with light effectively treat neoplastic tissue. Earlier and more accurate diagnosis Tumor tissue selective = > preserves normal tissue Excellent safety profile Well documented New standard for treatment of cancer Expanding technology applications into cosmetic field 3
4 Photocure was founded on research and close collaboration with DNR 4
5 Structured to maximize the potential of the Photodynamic Technology Platform Metvix Hexvix Lumacan Cevira Det Norske Radiumhospital University of Lausanne, Gothenburg, Quebec, Copenhagen, Berlin etc PCI Biotech Allumera Visonac Hexvix Speciality consultancies 5
6 Significant Milestones Achieved Marketing approval for Metvix Metvix/Aktilite approved in USA Lumacan licensed to Salix Start of Metvix clinical trials Metvix licensing agreement with Galderma Galderma s Metvix launch Hexvix approved in EU PCI Biotech spun out Cysview approved in USA Filed marketing application for Metvix Filed marketing application for Hexvix Marketing approval for Hexvix Hexvix licensing agreement with GE Healthcare Divested Metvix/Aktilite to Galderma Launched Allumera Listed on OSE Start of Hexvix clinical trials 6
7 Successful indication specific deal history -PHO chose an indication specific strategy with several deals based on the same IP/compound: Galderma - Skin cancer GE - Bladder cancer Salix - Colon cancer - Cervical cancer currently looking for partners -Which enables own commercialization in selected indication/markets 7
8 Metvix/Metvixia Treatment of skin cancer (AK/BCC)
9 Hexvix /Cysview - Bladder cancer diagnostics
10 Lumacan - Colorectal cancer Colorectal cancer is a large and growing health problem Among the most lethal cancers in men and women Estimated 15M colonoscopies performed annually in US Lumacan detects more polyps and tumors (i.e. small and flat) Fluorescence seen in all segments of the colon Leads to earlier local curative surgery Improves diagnosis and treatment 10
11 Cevira - HPV related disease No therapeutics available for HPV related disease Patients attend tedious follow up visits or require surgical procedures associated with severe morbidity Promising clinical results Positive market research Positive regulatory feed-back Looking for partner(s) 11
12 Commericialisation through indication specific partners have advantages - Benefits - Upfront/milestones dedicated to each indication higher valuation likely - Dedicated partners with strategic interests in the indication increases the chances for R&D and commercial success -Benefits to the licensee: - Lower price than whole - not paying for potential upsides never explored - De-risked asset, (e.g. Colon cancer API is already FDA approved when the product in phase 1/2) 12
13 and enables own commercialization in selected indications in selected markets >5,000 potential targets 1,500 in top 10 territories being targeted Managing white space with call center 13
14 Allumera - Photodynamic Cosmetic Allumera is the first Photodynamic Cosmetic specifically formulated to improve the overall appearance of skin, reduce outward signs of aging and minimize the appearance of pores with minimal down time and results that last 14 6 individually boxed $120/unit
15 Visonac - Acne There is a medical need for new alternatives to oral antibiotics and isotretinoin FDA concerned about current off-label use of isotretinoin for non nodular cystic acne Intended use for Visonac is moderate to severe acne excluding nodular cystic acne Before treatment Aim to be the first PDT product for treatment of acne vulgaris 15 After treatment
16 Totally Photocure has a strong pipeline and IP Position Clinical pipeline: Technology Indication Pre- Clinical Phase I Phase II Phase III Market Status Hexvix Cevira PDD PDT Detection of bladder cancer Treatment of precursors of cervical cancer Marketed in Europe and US Phase IIb Lumacan PDD Detection of colon cancer Licensed to Salix Visonac Allumera PDT PDC Treatment of moderate to severe acne Cosmetic for improving the appearance of skin Phase IIb Marketed in the US by Photocure 16
17 And a strategy to maximize the return of assets and capabilities Objectives: 17 Build a profitable specialty pharma company Maximise potential of innovative Photodynamic Technology platform Strategy: Cancer: Leverage proven experience to develop, register and commercialise new products in dermatology and cancer Develop to Proof of Concept and partner before Phase III Retain rights to co-market selected products in selected territories Dermatology: Develop, register and commercialise own products Establish dermatology operation in the US
18 Summary -Photocure founded on research and close collaboration with DNR -Structured to maximise the potential of the Photodynamic Technology Platform -Significant Milestones Achieved -Commercialisation through indication specific partners and own commercialization -Photocure - The World Leader in Photodynamic Technology (PDT) 18
19 19
20 Profit & Loss First quarter 2011 Sales revenue up 21% in Q1 R&D expenses of NOK 13 million as Salix has assumed the clinical development for Lumacan M&S expenses increased to NOK 10.7 million as US business established Other comprehensive income relates to changes in value of shareholding in PCI Biotech Numbers in NOK million Q Q FY 2010 Sales revenue Signing fee & milestone revenues Total revenues Cost of products sold Gross profit Other income Indirect manufacturing expenses R&D expenses Marketing & sales expenses Business development & admin Operating profit/ (loss) (EBIT) (17.5) (15.7) 7.5 Net financial items Net profit/ (loss) (15.9) (13.9) 18.1 Other comprehensive income Comprehensive income (13.9)
21 Balance sheet NOK 362 million in cash & cash equivalents at 31 March 2011 Other investments includes NOK 72 million in shares in PCI Biotech Shareholder s equity of NOK 442 million Other paid-in capital includes own shares of NOK 43 million Equity ratio of 91% No interest bearing debt Numbers in NOK million Machinery & Equipment Other investments Total non-current assets Inventory Receivables Cash & cash equivalents Total current assets Total assets Share capital Other paid-in capital Retained earnings Shareholders equity Long-term liabilities Current liabilities Total liabilities Total equity and liabilities
22 Cash Flow First quarter 2011 Numbers in NOK thousand Q Q FY 2010 Profit/ loss before tax (15.9) (13.9) 18.1 Depreciation and amortisation Share-based compensation Net interests (2.1) (2.4) (10.1) Changes in working capital (4.3) (9.8) 11.8 Other operational items (2.8) (3.1) (11.0) Net cash flow from operations (22.7) (27.6) 15.6 Cash flow from investments (8.3) Cash flow from capital transactions (5.5) (8.1) (21.5) Net change in cash (27.3) (33.6) (14.3) Cash & cash equiv. start of period Cash & cash equiv. end of period
23 Segment information Q Q Q % vs. Cancer Cancer Derm (3) Total 2010 Derm (2) Numbers in NOK thousand Own Partner R&D (2) Own Partner R&D Total Sales Hexvix (1) % Milestone revenues Cost of goods sold % Gross profit % Gross profit % 93% 88% 56% 80% 94% 135% 100% 114% Operating expenses % Operating profit/loss (-) (7.6) (13.1) (17.5) 11% (12.0) (11.7) (15.7) Net finance Profit/loss (-) before tax (15.9) 15% (13.9) (1) Deferred revenue from Metvix divestment is included (2) Including share of administrative expenses (3) R&D Visonac / Allumera and share of administrative expenses 23
Presentation of second quarter 2010 results
Brilliance in photodynamic technology TM Building a Specialty Pharma company Presentation of second quarter 2010 results 19 August 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO Photocure is
More informationThe world leader in photodynamic technology
Brilliance in photodynamic technology TM The world leader in photodynamic technology Presentation of third quarter 2010 results 27 October 2010 Kjetil Hestdal, President & CEO Christian Fekete, CFO The
More informationPHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY
PHOTOCURE ASA BUILDING A SPECIALTY PHARMA COMPANY RESULTS OF THE FIRST QUARTER 2013 25 April 2013 Kjetil Hestdal, MD, President & CEO Erik Dahl, CFO DISCLAIMER The information included in this Presentation
More informationBrilliance in photodynamic technology TM. Third quarter 2007. October 26th, 2007
Brilliance in photodynamic technology TM Third quarter 2007 October 26th, 2007 Hexvix commercialisation on track Denmark and Germany gaining momentum Hexvix revenue from GE Healthcare increased to MNOK
More informationPCI Biotech Holding ASA - Second Quarter Report 2008
PCI Biotech Holding ASA - Second Quarter Report 2008 Highlights Demerger and Initial Public Offering at Oslo Axess in June Raised NOK 60 million Per Walday, PhD hired as new CEO Board has been strengthened
More informationCONSOLIDATED STATEMENT OF INCOME
CONSOLIDATED STATEMENT OF INCOME 4 th quarter (a) 3 rd quarter 4 th quarter 2009 Sales 40,157 40,180 36,228 Excise taxes (4,397) (4,952) (4,933) Revenues from sales 35,760 35,228 31,295 Purchases, net
More informationMedistim ASA First Quarter 2016. Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO April 20th, 2016
Medistim ASA First Quarter 2016 Kari E. Krogstad, President and CEO Thomas Jakobsen, CFO April 20th, 2016 2 Disclaimer The information included in this Presentation contains certain forward-looking statements
More informationPROMETIC LIFE SCIENCES INC.
PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.
More informationQ4 Presentation. Oslo, 11 th February 2016. Svein W. F. Lien CEO
Q4 Presentation Oslo, 11 th February 2016 Svein W. F. Lien CEO Agenda Highlights Q4 Financials BetaGlucans Advanced wound care Enzymes Molecular testing Outlook Biotec Pharmacon ASA 2 Highlights Q4 Quarterly
More informationQ3 2015. Oslo 12 November 2015 Baard Schumann, CEO Sverre Molvik, CFO
Q3 2015 Oslo 12 November 2015 Baard Schumann, CEO Sverre Molvik, CFO Agenda Highlights Operational update Financial update Market Outlook and summary 2 HIGHLIGHTS Highlights Q3 2015 Continued strong margins
More informationInterim report 1st quarter 2016
Interim report 1st quarter 2016 About Komplett Bank ASA Komplett Bank ASA started banking operations on 21 March 2014 when the company received its banking licence from the Norwegian authorities. Komplett
More informationFinancial Results. siemens.com
s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014
More informationChina Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results
China Pharma Holdings, Inc. Reports Second Quarter 2010 Financial Results HAIKOU CITY, China, August 10, 2010 China Pharma Holdings, Inc. (NYSE AMEX: CPHI) ( China Pharma or the Company ), a leading fully
More information2015 Quarterly Report II
2015 Quarterly Report II 2 Key data Eckert & Ziegler 01 06/2015 01 06/2014 Change Sales million 69.0 61.9 + 11 % Return on revenue before tax % 16 % 9 % + 87 % EBITDA million 15.6 9.7 + 61 % EBIT million
More informationQ1 Results 2014. Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO. Stockholm 8 May 2014
Q1 Results 2014 Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO Stockholm 8 May 2014 Highlights Q1 2014 Business Q1 US FDA approved Alprolix Kiobrina pivotal phase 3 study did not meet
More informationConsolidated balance sheet
Consolidated balance sheet Non current assets 31/12/2009 31/12/2008 (*) 01/01/2008 (*) Property, plant and equipment 1,352 1,350 1,144 Investment property 7 11 11 Fixed assets held under concessions 13,089
More informationINTERIM REPORT 2015 SECOND QUARTER (Q2)
INTERIM REPORT 2015 SECOND QUARTER (Q2) Summary - Revenue in the second quarter came to 519 million kroner, 122 million kroner higher than the second quarter of 2014 - Higher revenue was a result of increased
More informationINTERIM REPORT 2014 SECOND QUARTER (Q2)
INTERIM REPORT 2014 SECOND QUARTER (Q2) Summary - Revenue in the second quarter came to 397 million kroner, 35 million kroner lower than the second quarter of 2013 - Lower revenue was a result of decreased
More informationINTERIM REPORT Q1 2016 PROTECTOR FORSIKRING ASA
INTERIM REPORT Q1 2016 PROTECTOR FORSIKRING ASA (UNAUDITED) APRIL 2016 Highlights Q1 2016 Growth 26% - First UK client on board Protector delivers a strong premium growth for the first quarter of 2016,
More informationRatio Analysis. A) Liquidity Ratio : - 1) Current ratio = Current asset Current Liability
A) Liquidity Ratio : - Ratio Analysis 1) Current ratio = Current asset Current Liability 2) Quick ratio or Acid Test ratio = Quick Asset Quick liability Quick Asset = Current Asset Stock Quick Liability
More information2 N D Q U A R T E R 2 0 1 6. O s l o, 1 8 J u l y 2 0 1 6
2 N D Q U A R T E R 2 1 6 O s l o, 1 8 J u l y 2 1 6 Agenda Per A Sørlie, President & CEO Highlights Business areas Outlook Per Bjarne Lyngstad, CFO Financial performance 2 Highlights 2 nd quarter 216
More informationMedical Billing and the Advantages of a Novelized Pharmaceutical Program
FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported
More informationCondensed consolidated income statement
RESTATED AND PREVIOUSLY COMMUNICATED (OLD) QUARTERLY INFORMATION FOR Fortum signed the agreement to sell its Swedish distribution business on 13 March 2015, which concludes Fortum s divestment of its electricity
More informationHalf Year 2015 Results
Half Year 2015 Results Letter to shareholders LifeWatch First Half Highlights Revenue growth of 9.1% to USD 52.5 million Above-market growth of over 12% in core monitoring services resulting in market
More informationFINANCIAL REPORT Q4 2015
CRAYON GROUP HOLDING AS FINANCIAL REPORT Q4 2015 Management commentary Q4 2015 Crayon continues to invest in geographic expansion centred on Software Asset Management (SAM) and cloud first, providing its
More information2-8. Identify whether each of the following items increases or decreases cash flow:
Problems 2-8. Identify whether each of the following items increases or decreases cash flow: Increase in accounts receivable Increase in notes payable Depreciation expense Increase in investments Decrease
More informationAPPENDIX 1 The Statement of Financial Position
APPENDIX 1 The Statement of Financial Position 1. Assets: the resources of the organization which are used to provide service and generate value 2. Current assets: assets which can be converted to cash
More informationINTERIM REPORT 2012 FOURTH QUARTER (Q4)
INTERIM REPORT 2012 FOURTH QUARTER (Q4) Summary - In January 2013 Norway Seafoods entered into an agreement to sell most of the company s Farming operations in France - Revenue in the fourth quarter came
More informationAbout Komplett Bank ASA. Outlook. Developments to date
Interim report 3 rd quarter 2015 About Komplett Bank ASA Komplett Bank ASA started banking operations on 21 March 2014 when the company received its banking licence from the Norwegian authorities. Komplett
More informationNORWAY ROYA L S A L M ON PRESENTATION Q2 2015. Oslo, 26 August 2015 Charles Høstlund, CEO Ola Loe, CFO
PRESENTATION Q2 2015 Oslo, 26 August 2015 Charles Høstlund, CEO Ola Loe, CFO AGENDA: Highlights for the period Segment information Group financials Markets Outlook 2 Highlights in Q2 2015 NORWAY ROYA L
More informationH1 2015 Audio webcast RESULTS PRESENTATION. July 30, 2015
H1 2015 Audio webcast RESULTS PRESENTATION July 30, 2015 DISCLOSURE This presentation contains no confidential material and may include publicly available market information which has not been independently
More information3. CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS
3. CONSOLIDATED QUARTERLY FINANCIAL STATEMENTS (1) Consolidated Quarterly Balance Sheets September 30, 2014 and March 31, 2014 Supplementary Information 2Q FY March 2015 March 31, 2014 September 30, 2014
More information2014 FIRST QUARTER RESULTS CONFERENCE CALL. May 15th, 2014
2014 FIRST QUARTER RESULTS CONFERENCE CALL May 15th, 2014 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The
More informationSummary of Financial Report for the FY ending March 2015 (Non-Consolidated)
Summary of Financial Report for the FY ending March 2015 (Non-Consolidated) April 30, 2015 Listed Company Name: Japan Tissue Engineering Co., Ltd. Listed Securities Exchange: JQ Stock Code: 7774 URL http://www.jpte.co.jp
More informationVITROLIFE S PRESS RELEASE OF ANNUAL ACCOUNTS 2001
PRESSRELEASE FEBRUARY 12, 2002 VITROLIFE S PRESS RELEASE OF ANNUAL ACCOUNTS 2001 The group's total net sales was SEK 100.1 million, compared with SEK 82.2 million the year before, equivalent to an increase
More informationSORIN GROUP ANNOUNCES FINAL FINANCIAL RESULTS FOR 2014
Press Release SORIN GROUP ANNOUNCES FINAL FINANCIAL RESULTS FOR 2014 Consolidated results for 2014: Revenues were 746.9 million, up 3.4% 1 compared to 2013; Adjusted net profit 2 was 55.1 million compared
More informationAbout Komplett Bank ASA. Outlook. Developments to date
Interim report 4th quarter 2015 About Komplett Bank ASA Komplett Bank ASA started banking operations on 21 March 2014 when the company received its banking licence from the Norwegian authorities. Komplett
More informationIpsen Jefferies Healthcare Conference
Ipsen Jefferies Healthcare Conference November 2015 IPSEN pour nom de la société - 07/04/2011 / page 1 Disclaimer This presentation includes only summary information and does not purport to be comprehensive.
More informationThird quarter results 2015
1 Third quarter results 2015 30 October 2015 Peter A. Ruzicka, President & CEO Improved performance in the third quarter 2.3% organic growth 1 15% EBIT (adj.) 2 growth in BCG 57% increase in EPS 2 1 Reported
More informationACER INCORPORATED AND SUBSIDIARIES. Consolidated Balance Sheets
Consolidated Balance Sheets June 30, 2015, December 31, 2014, and (June 30, 2015 and 2014 are reviewed, not audited) Assets 2015.6.30 2014.12.31 2014.6.30 Current assets: Cash and cash equivalents $ 36,400,657
More informationTomTom Q4 2012 results. Harold Goddijn CEO Marina Wyatt CFO 12 February 2013
TomTom Q4 2012 results Harold Goddijn CEO Marina Wyatt CFO 12 February 2013 Summary of results Revenue of 1,057 million and adjusted EPS of 0.40 PND market performed as expected Automotive affected by
More informationLudwigshafen, February 25, 2014
Ludwigshafen, February 25, 2014 Analyst Conference FY2013 Cautionary note regarding forward-looking statements This presentation may contain forward-looking statements that are subject to risks and uncertainties,
More informationBiotest AG. Company Presentation. July 2013. Company Presentation EU. Biotest AG
Company Presentation July 2013 Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and asset situation of and its
More informationTheravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update DUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ:
More informationKLÖCKNER & CO GROUP FIGURES 2 INTERIM GROUP MANAGEMENT REPORT 3 KLÖCKNER & CO SHARE 20 CONSOLIDATED STATEMENT OF INCOME FOR THE SIX-MONTH PERIOD
KLÖCKNER & CO GROUP FIGURES 2 INTERIM GROUP MANAGEMENT REPORT 3 KLÖCKNER & CO SHARE 20 CONSOLIDATED STATEMENT OF INCOME FOR THE SIX-MONTH PERIOD ENDING JUNE 30, 2015 22 STATEMENT OF COMPREHENSIVE INCOME
More informationMEDTRONIC, INC. WORLD WIDE REVENUE (Unaudited)
WORLD WIDE REVENUE ($ millions) 1 2 3 4 1 2 3 4 FY11 FY11 FY11 FY11 FY11 FY12 FY12 FY12 FY12 FY12 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC RHYTHM DISEASE MANAGEMENT
More informationConsolidated Statement of Profit or Loss (in million Euro)
Consolidated Statement of Profit or Loss (in million Euro) Q3 2013 Q3 2014 % change 9m 2013 9m 2014 % change Revenue 689 636-7.7% 2,126 1,909-10.2% Cost of sales (497) (440) -11.5% (1,520) (1,324) -12.9%
More informationFinancial Statement and Cash Flow Analysis
Chapter 2 Financial Statement and Cash Flow Analysis Answers to Concept Review Questions 1. What role do the FASB and SEC play with regard to GAAP? The FASB is a nongovernmental, professional standards
More informationConsolidated Statement of Financial Position
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 30 JUNE 2014 Consolidated Statement of Financial Position in CHF 1,000 Note 30 June 2014 31 December 2013 (unaudited) (audited) Assets Non-current assets
More informationFINANCIAL RESULTS Q1 2012. 16 May 2012
FINANCIAL RESULTS Q1 2012 16 May 2012 Highlights Q1 2012 Satisfactory Q1 financials underlying EBITDA and profit before tax on a par with Q1 2011 - Lower power prices partly offset by increased power generation
More informationSoftware AG Results 1 st Quarter 2015 (IFRS, unaudited)
Software AG Results 1 st Quarter (IFRS, unaudited) April 29, 1 Safe Harbor This presentation includes forward-looking statements based on the beliefs of Software AG management. Such statements reflect
More informationDelta Galil Reports 2016 First Quarter Results
Delta Galil Reports 2016 First Quarter Results Sales Rise to $256.7 Million; Net Income to Shareholders is $7.9 Million Reaffirms 2016 Guidance; Sales Expected to Reach $1,090 Million-$1,110 Million and
More informationNORWAY ROYA L S A L M ON PRESENTATION Q1 2016. Oslo, 4 May 2016 Charles Høstlund, CEO Ola Loe, CFO 1
PRESENTATION Q1 2016 Oslo, 4 May 2016 Charles Høstlund, CEO Ola Loe, CFO 1 AGENDA: Highlights for the period Segment information Green licenses Group financials Markets Outlook 2 Highlights in Q1 2016
More informationPublic Joint Stock Company Kuzbasskaya Toplivnaya Company (trading as KTK ) Unaudit Condensed Interim Consolidated Financial Statements for the six
Public Joint Stock Company Kuzbasskaya Toplivnaya Company (trading as KTK ) Unaudit Condensed Interim Consolidated Financial Statements for the six months ended 30 June 2015 Contents Consolidated Statement
More informationMOLOGEN AG German Equity Forum 2015
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies
More informationNordic Mining ASA Interim Report per 30 March 2007
Nordic Mining ASA Interim Report per 30 March 2007 Nordic Mining ASA Nordic Mining is a mining company aiming for growth based on integrated activity within exploration, extraction and production of high-end
More informationStandard #2 If you right click on a Agenda slide in the left navigation bar you can choose between other slide layouts. TIP:
Annual Report 2014 Agenda 2 Full year results FY 2014 Exiqon Life Sciences Exiqon Diagnostics Corporate objective and investment case Financial calendar and outlook for 2015 Full year results 2014 - Q4
More informationQuarterly Shareholder Update December 2015
Quarterly Shareholder Update December 2015 Pharmaxis an emerging powerhouse in drug development Dear Shareholder, Pharmaxis commenced the December 2015 quarter with the foundations for future value firmly
More informationDRAFT Immune System Therapeutics Limited (Administrators Appointed)( ISTL ) First meeting of creditors 16 October 2014 Agenda Formalities Purpose of meeting Purpose of administration Background Financial
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationA strong third quarter
A strong third quarter Interim presentation for the third quarter 2015 Stockholm, 5 November 2015 Anders Nissen, CEO Liia Nõu, CFO Today s agenda Introduction Financial review Business model and value
More informationResults 3 rd Quarter 2009
1 Results 3 rd Quarter 20 October 29 th 20 Sven Tore Kaasa, CEO Kjetil Haukås, CFO Perspectives on TeleComputing 2 Well positioned in attractive part of the outsourcing market The long awaited market growth
More information19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com.
19 October 2006 Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009 By email; announcements@bsx.com.au RE: Announcement by State Development Fund Limited Please
More informationVizrt Group AS Reports Q1 2015 Results
Vizrt Group AS Quarterly report March 31, 2015 Vizrt Group AS Reports Q1 2015 Results Business Overview On March 19, 2015, Vizrt Group AS (formerly Aksjeselskapet av 17. Oktober 2014 AS ) ( the Company
More informationConsolidated Statement of Profit or Loss (in million Euro)
Consolidated Statement of Profit or Loss (in million Euro) Q3 2014 Q3 2015 % change 9m 2014 9m 2015 % change Revenue 636 661 3.9% 1,909 1,974 3.4% Cost of sales (440) (453) 3.0% (1,324) (1,340) 1.2% Gross
More informationCytec Announces First Quarter 2010 Results. As-Adjusted EPS of $0.66, Significantly Above Prior Year As-Adjusted EPS of $0.06
cytec News & Information Cytec Industries Inc. Five Garret Mountain Plaza Woodland Park, New Jersey 07424 www.cytec.com Contact: Jodi Allen (Investor Relations) (973) 357-3283 Release Date: Immediate Cytec
More informationNORWEGIAN CRUISE LINE HOLDINGS LTD. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data)
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data) Revenue Passenger ticket $ 583,923 $ 490,322 $ 1,400,470 $ 1,257,871 Onboard and other 213,962 184,089 569,479
More informationLonmin Plc Adoption of International Financial Reporting Standards. Unaudited Restatement of Accounts
Lonmin Plc Adoption of International Financial Reporting Standards Unaudited Restatement of Accounts Financial highlights Relatively limited impacts on profitability for the year to 30 September 2005 under
More informationQ1 2016 Results Conference Call
Q1 2016 Results Conference Call Karim Bohn, CFO 10 May 2016 PATRIZIA Immobilien AG PATRIZIA Bürohaus Fuggerstrasse 26 86150 Augsburg T +49 821 50910-000 F +49 821 50910-999 immobilien@patrizia.ag www.patrizia.ag
More informationMGC Diagnostics Corporation Reports Fiscal Year 2015 Financial Results
MGC Diagnostics Corporation 350 Oak Grove Parkway Saint Paul, MN 55127 Telephone: (651) 484-4874 Facsimile: (651) 484-4826 FOR IMMEDIATE RELEASE MGC Diagnostics Corporation Reports Fiscal Year 2015 Financial
More information2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q
2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationSummary of Business Report for the Fifth Fiscal Year ended December 31, 2012
February 15, 2013 Summary of Business Report for the Fifth Fiscal Year ended December 31, 2012 RaQualia Pharma Inc. (4579, Osaka Stock Exchange, Growth Market) today reported financial results for the
More informationTransgene in 2007: Partnership and Refinancing Position the Company for its Future Development
Strasbourg, 11 March 2008 Transgene in 2007: Partnership and Refinancing Position the Company for its Future Development Strasbourg, France, March 11, 2008 Transgene (Euronext Paris: FR0005175080) announces
More informationPharming Group NV (Euronext: PHARM)
Pharming Group NV (Euronext: PHARM) Sijmen de Vries, MD, MBA Chief Executive Officer Annual General Meeting of Shareholders Leiden, 30 April 2015 1 Safe harbour statement The information contained in this
More informationPresented at: Jefferies 2015 Global Healthcare Conference
Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution
More informationOslo Børs VPS Holding ASA 2nd Quarter 2015
Oslo Børs VPS Holding ASA 2nd Quarter 215 12 August 215 2nd quarter at a glance Good level of trading and settlement activity continued in the quarter Continuing strong interest in admission of both shares
More informationManagement Presentation Q2/2012 Results. 8 August 2012
Management Presentation Q2/2012 Results 8 August 2012 Cautionary statement This presentation contains forward-looking statements which involve risks and uncertainties. The actual performance, results and
More informationI. Consolidated Balance Sheet
I. Consolidated Balance Sheet Note At 30 2013 At 31 December ASSETS Non-current assets Property, plant and equipment 3.2 361 738 357 715 Goodwill 3.3 44 061 44 061 Other intangible assets 3.4 82 472 96
More informationFull Year 2012 Results. Madrid, February 28 th, 2013
Full Year 2012 Results Madrid, February 28 th, 2013 Our progress in 2012 1. A new company identity and mission 2. A fully integrated organization 3. A strong plan going forward 4. Solid business and financial
More informationCONFERENCE CALL Q1-Q3 2010. 10 November 2010
CONFERENCE CALL Q1-Q3 2010 10 November 2010 Agenda Overview Q1-Q3 Q3 2010 Dr Helmut Leube, Chairman of the Management Board Key financials i Q1-Q3 Q3 2010 Dr Margarete Haase, CFO Outlook Dr Helmut Leube,
More informationThe Nature of Accounting Systems
Basic Accounting & Budgeting February 4, 2009 The Nature of Accounting Systems Accounting is the process of recording, classifying, summarizing, reporting and interpreting information about the economic
More informationStrong first quarter sales growth in all business groups
Strong first quarter sales growth in all business groups Agfa-Gevaert announced its first quarter results. All business groups reported solid sales, leading to an increase in Group sales of 8.1 percent
More informationPfeiffer Vacuum announces results for FY 2014
PRESS RELEASE Pfeiffer Vacuum announces results for FY 2014 Total sales of 406,6 million EBIT margin at 11,0 percent Dividend proposal of 2.65 euros Asslar, Germany, March 26, 2015. Total sales for FY
More information20 May 2015 OpenLimit Holding AG. FIRST BERLIN Equity Research
FIRST ERLIN Equity Research RATING Switzerland / Software Primary exchange: Frankfurt Q1 figures PRICE TARGET 1.10 loomberg: O5H GR Return Potential 37.3% ISIN: CH0022237009 Risk Rating High STRONG SALES
More informationAnnual Report & Accounts 2012
Allergy Therapeutics plc Annual Report & Accounts 2012 Interim Report for the six months ended 31 December 2012 www.allergytherapeutics.com www.pollinex.com Highlights At a Glance Revenue 25.7m (H1 2012:
More informationConsolidated and Non-Consolidated Financial Statements
May 13, 2016 Consolidated and Non-Consolidated Financial Statements (For the Period from April 1, 2015 to March 31, 2016) 1. Summary of Operating Results (Consolidated) (April 1,
More informationIBM Finans Norge AS. Condensed Interim Financial Statements. 31 March 2015
Condensed Interim Financial Statements Condensed Interim Financial Statements For the Quarter Ended Contents Page Condensed Interim Statement of Comprehensive Income 2 Condensed Interim Statement of Financial
More informationTelio Holding ASA Q1 08 presentation. Eirik Lunde, CEO Oslo, 29 April 2008
Telio Holding ASA Q1 08 presentation Eirik Lunde, CEO Oslo, 29 April 2008 Telio Holding ASA Leading European broadband telephony provider Committed to improving user experience and reducing cost to subscribers
More informationHOPKINTON, Mass., April 24, 2013 - HIGHLIGHTS:
HOPKINTON, Mass., April 24, 2013 - HIGHLIGHTS: Record first-quarter revenue, non-gaap net income, non-gaap EPS, operating cash flow and free cash flow Year-over-year revenue growth across U.S. and major
More informationEmployees Employees as at 31 August 53 44 20.5 Employees average during the reporting period 52 44 18.2
9M 2007 9M 2006 Change in % Earnings key figures in EUR 000 Other operating income 2,158 966 123.4 Operating expenses (19,486) (13,149) 48.2 of which research and development (16,606) (10,527) 57.8 Operating
More informationQ4 2015. Oslo 15 February 2016 Baard Schumann, CEO Sverre Molvik, CFO
Q4 2015 Oslo 15 February 2016 Baard Schumann, CEO Sverre Molvik, CFO Agenda Highlights Operational update Financial update Market Outlook and summary 2 HIGHLIGHTS Highlights Q4 and FY 2015 Strong sales:
More informationWILEX AG: Interim management statement on the first quarter of 2016
WILEX AG: Interim management statement on the first quarter of 2016 Munich, Germany, 14 April 2016. WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today reported on the first three months of the 2016 financial
More informationPharming Group NV (RUCONEST) Chemicals
Pharming Group NV Interim Report January - September Leiden, The Netherlands, 28 October, Biotech company Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) presents its (unaudited)
More informationAffitech A/S reports financial result for the first six months of 2012
Release no. 23/2012 Affitech A/S reports financial result for the first six months of 2012 Clinical trials sites initiated in Russia in late June 2012 by Affitech s collaboration partner IBC Generium for
More informationDATRON AG. Investor day supports our positive view. Buy (Buy) 12.50 EUR (12.50 EUR ) BANKHAUS LAMPE // 1 17/09/2015
BANKHAUS LAMPE // 1 DATRON AG Investor day supports our positive view 17/09/2015 Buy (Buy) 12.50 EUR (12.50 EUR ) Close 15/09/2015 9.75 EUR Bloomberg: DAR GY WKN: A0V9LA Sector Engineering Share price
More informationINTERIM REPORT 2013 SECOND QUARTER (Q2)
INTERIM REPORT 2013 SECOND QUARTER (Q2) Summary - Revenue in the second quarter came to 432 million kroner, 39 million kroner higher than the second quarter of 2012 - Higher revenue was a result of increased
More information2014 HALF YEAR RESULTS 4 September 2014
862m H1 2014 Revenues 2014 HALF YEAR RESULTS 4 September 2014 57% of Revenues for International in H1 2014 21,657 Employees In H1 2014 Disclaimer This presentation contains forward-looking statements (as
More information2 Quarterly Report 02 Ratios. Jan Jun/2012 Jan Jun/2011 Change. Sales Million EUR 57.9 55.8 4% Return on revenue before tax % 16% 20% 23%
Quarterly Report II 2 Quarterly Report 02 Ratios Jan Jun/ Jan Jun/ Change Sales Million EUR 57.9 55.8 4% Return on revenue before tax % 16% 20% 23% EBITDA Million EUR 13.8 15.4 11% EBIT Million EUR 10.0
More informationJuly September 2013. July September 2014
Interim Report Interim Report Sales in the quarter increased to SEK 225.1 (216.9) million. In local currencies the decrease was 1.1 per cent. Operating profit for the quarter was SEK 12.9 (5.7) million.
More information2014 Quarterly Report II
2014 Quarterly Report II 2 Key data Eckert & Ziegler 01 06/2014 01 06/2013 Change Sales million 61.9 55.3 12% Return on revenue before tax % 9 % 12 % 26 % EBITDA million 9.7 10.2 5 % EBIT million 6.2 6.9
More information